Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Retained Earnings
The retained earnings for Labcorp Holdings Inc. (LH) is $8.64 Billion with a year-over-year change of +4.05%. Retained earnings represent the cumulative net income that has been kept by the company rather than distributed to shareholders as dividends. It's a key component of shareholders' equity.
LH Retained Earnings Chart
LH Retained Earnings
$8.64B+546.55% 20Y
Zoom
Current Retained Earnings
$8.64B
$8.64 Billion
Year-over-Year Change
+4.05%
vs. $8.30B prior year
Historical Data
30
Years of data available
Annual Retained Earnings History
| Year | Retained Earnings | YoY Change | % Change |
|---|---|---|---|
| 2025 | $8.64B | +$336.50M | +4.05% |
| 2024 | $8.30B | +$415.20M | +5.26% |
| 2023 | $7.89B | $-2.69B | -25.45% |
| 2022 | $10.58B | +$125.30M | +1.20% |
| 2021 | $10.46B | +$977.20M | +10.31% |
| 2020 | $9.48B | +$1.58B | +19.94% |
| 2019 | $7.90B | +$823.80M | +11.64% |
| 2018 | $7.08B | +$855.80M | +13.75% |
| 2017 | $6.22B | +$1.27B | +25.59% |
| 2016 | $4.96B | +$732.80M | +17.35% |
| 2015 | $4.22B | +$436.90M | +11.54% |
| 2014 | $3.79B | +$412.60M | +12.23% |
| 2013 | $3.37B | $-215.00M | -5.99% |
| 2012 | $3.59B | +$201.30M | +5.94% |
| 2011 | $3.39B | +$140.60M | +4.33% |
| 2010 | $3.25B | +$318.70M | +10.88% |
| 2009 | $2.93B | +$327.90M | +12.61% |
| 2008 | $2.60B | +$356.30M | +15.88% |
| 2007 | $2.24B | +$475.80M | +26.91% |
| 2006 | $1.77B | +$431.60M | +32.30% |
| 2005 | $1.34B | +$386.20M | +40.65% |
| 2004 | $950.10M | +$363.00M | +61.83% |
| 2003 | $587.10M | +$321.00M | +120.63% |
| 2002 | $266.10M | +$254.60M | +2213.91% |
| 2001 | $11.50M | +$179.50M | +106.85% |
| 2000 | $-168.00M | +$77.50M | +31.57% |
| 1999 | $-245.50M | +$15.00M | +5.76% |
| 1998 | $-260.50M | +$24.40M | +8.56% |
| 1997 | $-284.90M | $-130.80M | -84.88% |
| 1996 | $-154.10M | — | — |
Related Metrics
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter